In addition, novel microenvironment‐based DLBCL classification suggests that tumor immune context impacts R‐CHOP treatment outcomes as a prognostic factor independent of COO classification [33]. This evidence concerns the gene DDIT3 and diffuse large B-cell lymphoma.